Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
-
2021 SS
- Kurs: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 3
- begl. Vorlesung: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 2
- Der nuklearmedizinische Fall der Woche: Bildbeispiele, Indikationen und Grundlagen
- Klinische Nuklearmedizin: Grundlagen und Indikationen
- Anleitung zu selbständigen wissenschaftlichen Arbeiten in der Nuklearmedizin
- Kurs: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 1
- PJ - Seminar
- Kurs: Bildgebende Verfahren, Strahlenbehandlung, Strahlenschutz - Teil 2
-
2020 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in MenIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 4, S. 598 - 604ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer PatientsIn: Cancers Jg. 15 (2023) Nr. 8,ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access)
-
Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on ¹⁸F-FDG PET/MRI and Machine LearningIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 2, S. 304 - 311ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
DGN-Handlungsempfehlung (S1-Leitlinie) : PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms - Stand: 01/2022 - AWMF-Registernummer: 031-055In: Nuklearmedizin = Nuclear Medicine Jg. 62 (2023) Nr. 1, S. 5 - 19ISSN: 2567-6407; 0029-5566Online Volltext: dx.doi.org/
-
Evaluation of thresholding methods for the quantification of [⁶⁸Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapyIn: European Journal of Nuclear Medicine and Molecular Imaging (2023) in pressISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein Inhibitor Theranostics : The Case for Use in SarcomaIn: PET Clinics (2023) in pressISSN: 1879-9809; 1556-8598Online Volltext: dx.doi.org/
-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 5, S. 711 - 716ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Is There a Role of Artificial Intelligence in Preclinical Imaging?In: Seminars in Nuclear Medicine (2023) in pressISSN: 1558-4623; 0001-2998Online Volltext: dx.doi.org/
-
Molecular Imaging of Lymphoma : Future Directions and PerspectivesIn: Seminars in Nuclear Medicine Jg. 53 (2023) Nr. 3, S. 449 - 456ISSN: 1558-4623; 0001-2998Online Volltext: dx.doi.org/
-
Novel ⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine-Related PitfallsIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 3, S. 368 - 371ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
PSMA PET/CT : Joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 5, S. 1466 - 1486ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
PSMA-Directed Imaging and Therapy of Salivary Gland Tumors : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 3, S. 372 - 378ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancerIn: Endocrine Connections Jg. 12 (2023) Nr. 2,ISSN: 2049-3614Online Volltext: dx.doi.org/ (Open Access)
-
Rabbit fever : granulomatous inflammation by Francisella tularensis mimics lung cancer in dual tracer ¹⁸FDG and ⁶⁸Ga-FAPI PET/CTIn: European Journal of Nuclear Medicine and Molecular Imaging (2023)ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision : A phantom studyIn: The Quarterly Journal of Nuclear Medicine and Molecular Imaging Jg. 67 (2023) Nr. 1, S. 57 - 68ISSN: 1827-1936; 0392-0208; 1824-4785Online Volltext: dx.doi.org/
-
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET : Imaging Neuroendocrine TumorsIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 2, S. 204 - 210ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Safety and Survival Outcomes of ¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior ²²³Ra treatment : The RALU StudyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 64 (2023) Nr. 4, S. 574 - 578ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)In: European Urology Jg. 83 (2023) Nr. 5, S. 405 - 412ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/ (Open Access)
-
Using PSMA imaging for prognostication in localized and advanced prostate cancerIn: Nature Reviews Urology Jg. 20 (2023) Nr. 1, S. 23 - 47ISSN: 1759-4820; 1759-4812Online Volltext: dx.doi.org/
-
68Ga-FAPI as a Diagnostic Tool in Sarcoma : Data from the 68Ga-FAPI PET Prospective Observational TrialIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 1, S. 89 - 95ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
A Role for PET/CT in response assessment of malignant pleural mesotheliomaIn: Seminars in Nuclear Medicine Jg. 52 (2022) Nr. 6, S. 816 - 823ISSN: 1558-4623; 0001-2998Online Volltext: dx.doi.org/
-
A Role of PET/MR in Breast Cancer?In: Seminars in Nuclear Medicine Jg. 52 (2022) Nr. 5, S. 611 - 618ISSN: 1558-4623; 0001-2998Online Volltext: dx.doi.org/
-
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in MiceIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 9, S. 1357 - 1363ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Comparison of nodal staging between CT, MRI, and [¹⁸F]-FDG PET/MRI in patients with newly diagnosed breast cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) S. 992 - 1001ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
Correction to : Value of PET imaging for radiation therapyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 198 (2022) Nr. 1, S. 80 - 82ISSN: 1439-099X; 0179-7158Online Volltext: dx.doi.org/ (Open Access)
-
Diagnostic Performance of ¹²⁴I-Metaiodobenzylguanidine PET/CT in Patients with PheochromocytomaIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 6, S. 869 - 874ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Effects of Anti-Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis : A Prospective Proof-of-Concept Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and SpineIn: Arthritis & Rheumatology Jg. 74 (2022) Nr. 9, S. 1497 - 1505ISSN: 2326-5191; 2326-5205Online Volltext: dx.doi.org/
-
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI) : A Single-Center Prospective Two-Arm StudyIn: Clinical Cancer Research Jg. 28 (2022) Nr. 19, S. 4194 - 4202ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/ (Open Access)
-
FDG-PET Positivity and Overall Survival in Renal Cell CarcinomaIn: JAMA Network Open Jg. 5 (2022) Nr. 11,ISSN: 2574-3805Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
First experiences with dynamic renal [⁶⁸Ga]Ga-DOTA PET/CT : A comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rateIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. 10, S. 3373 - 3386ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
Free-breathing 3D Stack of Stars GRE (StarVIBE) sequence for detecting pulmonary nodules in 18F-FDG PET/MRIIn: EJNMMI Physics Jg. 9 (2022) Nr. 1,ISSN: 2197-7364Online Volltext: dx.doi.org/ (Open Access)
-
Fully Automated, High-Dose Radiosynthesis of [18F]PARPiIn: Pharmaceuticals Jg. 15 (2022) Nr. 7,ISSN: 1424-8247Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Improved production of ⁶⁸Ga-Pentixafor using cartridge mediated cation exchange purificationIn: Applied Radiation and Isotopes Jg. 189 (2022)ISSN: 1872-9800; 0969-8043Online Volltext: dx.doi.org/
-
Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors : A Case Series of 9 PatientsIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 5, S. 727 - 734ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification : A post-hoc analysis of the PETAL trialIn: Leukemia (2022) in pressISSN: 1476-5551; 0887-6924Online Volltext: dx.doi.org/ (Open Access)
-
Lesion Quantification Accuracy of Digital 90Y PET Imaging in the Context of Dosimetry in Systemic FAPI Radionuclide TherapyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) (2022) in pressISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT : comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteriaIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. 12, S. 4271 - 4281ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaIn: Cancer Imaging Jg. 22 (2022) Nr. 1,ISSN: 1470-7330; 1740-5025Online Volltext: dx.doi.org/ (Open Access)
-
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After ProstatectomyIn: International Journal of Radiation Oncology, Biology, Physics Jg. 113 (2022) Nr. 5, S. 1015 - 1024ISSN: 1879-355X; 0360-3016Online Volltext: dx.doi.org/
-
Multiparametric¹⁸F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast CancerIn: Cancers Jg. 14 (2022) Nr. 7,ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access)
-
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) : An International Multicenter StudyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 11, S. 1651 - 1658ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Onkologische Theranostik in der NuklearmedizinIn: Die Onkologie Jg. 28 (2022) Nr. 7, S. 612 - 622ISSN: 2731-7226; 2731-7234Online Volltext: dx.doi.org/
-
Onkologische Theranostik in der NuklearmedizinIn: Die Radiologie Jg. 62 (2022) Nr. 10, S. 875 - 884ISSN: 2731-7048; 2731-7056Online Volltext: dx.doi.org/
-
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups : An International Multicenter StudyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 1, S. 76 - 80ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients : A Multicenter Retrospective StudyIn: Cancers Jg. 14 (2022) Nr. 22,ISSN: 2072-6694Online Volltext: dx.doi.org/ (Open Access)
-
Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital systemIn: BMC Cancer Jg. 22 (2022) Nr. 1,ISSN: 1471-2407Online Volltext: dx.doi.org/ (Open Access)
-
Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET : A Pictorial AnalysisIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 6, S. 890 - 896ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Prostataspezifische Membranantigen-Positronenemissionstomographie (PSMA-PET) für Urologen : Wann und welcher Tracer?In: Der Urologe Jg. 61 (2022) Nr. 4, S. 384 - 391ISSN: 0375-4685; 1433-0563Online Volltext: dx.doi.org/ (Open Access)
-
Radiation Protection and Occupational Exposure on ⁶⁸Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted ProstatectomyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 9, S. 1349 - 1356ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/
-
Repeatability of ⁶⁸Ga-PSMA-HBED-CC PET/CT-Derived Total Molecular Tumor VolumeIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 5, S. 746 - 753ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 3, S. 396 - 398ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Response to letter to the editorIn: European Journal of Nuclear Medicine and Molecular Imaging (2022) in pressISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Jg. 28 (2022) Nr. 19, S. 4346 - 4353ISSN: 1557-3265; 1078-0432Online Volltext: dx.doi.org/ (Open Access)
-
Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET : Myth or Reality?In: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 63 (2022) Nr. 2, S. 226 - 232ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
¹⁸F-PSMA-11 Versus ⁶⁸Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer : A Prospective Double-blind Randomised Cross-over TrialIn: European Urology Jg. 82 (2022) Nr. 5, S. 501 - 509ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/
-
⁶⁸Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomasIn: Scientific Reports Jg. 12 (2022) Nr. 1,ISSN: 2045-2322Online Volltext: dx.doi.org/ (Open Access)
-
Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extensionIn: BMC Endocrine Disorders Jg. 21 (2021) Nr. 1,ISSN: 1472-6823Online Volltext: dx.doi.org/ (Open Access)
-
Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancerIn: EJNMMI Physics Jg. 8 (2021) Nr. 1,ISSN: 2197-7364Online Volltext: dx.doi.org/ (Open Access)
-
Determining the Axillary Nodal Status with 4 Current Imaging Modalities, Including 18F-FDG PET/MRI, in Newly Diagnosed Breast Cancer : A Comparative Study Using Histopathology as the Reference StandardIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 12, S. 1677 - 1683ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection : A Multicenter Prospective Phase 3 Imaging TrialIn: JAMA Oncology Jg. 7 (2021) Nr. 11, S. 1635 - 1642ISSN: 2374-2445; 2374-2437Online Volltext: dx.doi.org/ (Open Access)
-
Digital and respiratory-gated FDG PET/CT for characterization of lung lesionsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 83ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancerIn: Nuclear Medicine and Biology Jg. 96-97 (2021) S. 101 - 111ISSN: 1872-9614; 0969-8051Online Volltext: dx.doi.org/ (Open Access)
-
Enzalutamide enhances psma expression of psma-low prostate cancerIn: International Journal of Molecular Sciences (IJMS) Jg. 22 (2021) Nr. 14,ISSN: 1422-0067; 1661-6596Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
FDG-PET avidity as a prognostic biomarker for overall survival in renal cell carcinomaIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. Suppl. 15, S. e16564ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trialIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 2, S. 501 - 508ISSN: 1619-7089; 1619-7070Online Volltext: dx.doi.org/ (Open Access)
-
Head-to-head intra-individual comparison of biodistribution and tumor uptake of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in cancer patientsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 13, S. 4377 - 4385ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging : A Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 5, S. 675 - 678ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Imaging Inflammation with Positron Emission TomographyIn: Biomedicines Jg. 9 (2021) Nr. 2, S. 212ISSN: 2227-9059Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Just another “Clever Hans”? : Neural networks and FDG PET-CT to predict the outcome of patients with breast cancerIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 10, S. 3141 - 3150ISSN: 1619-7089; 1619-7070Online Volltext: dx.doi.org/ (Open Access)
-
Lung uptake detected by ⁶⁸Ga-PSMA-11 PET/CT in prostate cancer patients with SARS-CoV-2 : a case seriesIn: American Journal of Nuclear Medicine and Molecular Imaging Jg. 11 (2021) Nr. 4, S. 300 - 306ISSN: 2160-8407Online Volltext (Open Access)
-
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate CancerIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 7, S. 989 - 995ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
N-staging in large cell neuroendocrine carcinoma of the lung : diagnostic value of [¹⁸F]FDG PET/CT compared to the histopathology reference standardIn: EJNMMI Research Jg. 11 (2021) Nr. 1,ISSN: 2191-219XOnline Volltext: dx.doi.org/ (Open Access)
-
Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer : An international, multicentre, retrospective studyIn: The Lancet Oncology Jg. 22 (2021) Nr. 8, S. 1115 - 1125ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/ (Open Access)
-
Oldies (but Goldies) : Die Peritonealszintigrafie bei PeritonealdialyseIn: Nuklearmedizin Jg. 60 (2021) Nr. 06, S. 450 - 453ISSN: 0029-5566; 2567-6407Online Volltext: dx.doi.org/
-
PET/CT versus PET/MRT bei Kopf-Hals-TumorenIn: TumorDiagnostik & Therapie Jg. 42 (2021) Nr. 5, S. 354 - 360ISSN: 1439-1279; 0722-219XOnline Volltext: dx.doi.org/
-
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysisIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. 4, S. 1200 - 1210ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access)
-
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of diseaseIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 12, S. 1747 - 1750ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : study protocolIn: BMC Cancer Jg. 21 (2021)ISSN: 1471-2407Online Volltext: dx.doi.org/ (Open Access)
-
Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patientsIn: European Radiology Jg. 31 (2021) Nr. 11, S. 8714 - 8724ISSN: 1432-1084; 0938-7994Online Volltext: dx.doi.org/ (Open Access)
-
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC) : efficacy results of the UCLA cohortIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 10, S. 1440 - 1446ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging : Utilization of a short-pass filter to reduce technical pitfallsIn: Translational Andrology and Urology Jg. 10 (2021) Nr. 10, S. 3972 - 3985ISSN: 2223-4691; 2223-4683Online Volltext: dx.doi.org/ (Open Access)
-
Prostate-specific Membrane Antigen–based Imaging of Castration-resistant Prostate CancerIn: European Urology Focus Jg. 7 (2021) Nr. 2, S. 279 - 287ISSN: 2405-4569Online Volltext: dx.doi.org/
-
Prostate-specific membrane antigen PET in prostate cancerIn: Radiology Jg. 299 (2021) Nr. 2, S. 248 - 260ISSN: 1527-1315; 0033-8419Online Volltext: dx.doi.org/
-
Reply: The Importance of an Adequate Surgical Template During Salvage Lymph Node Dissection for Node-Recurrent Prostate CancerIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 7, S. 1022ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617 : Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312)In: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 10, S. 1447 - 1456ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Silicon-photomultiplier-based PET/CT reduces the minimum detectable activity of iodine-124In: Scientific Reports Jg. 11 (2021) Nr. 1,ISSN: 2045-2322Online Volltext: dx.doi.org/ (Open Access)
-
Theranostics in oncology : What radiologists want to knowIn: European Journal of Radiology Jg. 142 (2021)ISSN: 1872-7727; 0720-048XOnline Volltext: dx.doi.org/
-
Update from PSMA-SRT Trial NCT03582774 : A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical OutcomeIn: European Urology Focus Jg. 7 (2021) Nr. 2, S. 238 - 240ISSN: 2405-4569Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Value of PET imaging for radiation therapyIn: Nuklearmedizin Jg. 60 (2021) Nr. 5, S. 326 - 343ISSN: 2567-6407; 0029-5566Online Volltext: dx.doi.org/ (Open Access)
-
Value of PET imaging for radiation therapyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 179 (2021) Nr. 9, S. 757 - 779ISSN: 1439-099X; 0179-7158Online Volltext: dx.doi.org/ (Open Access)
-
Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI PETIn: Clinical Nuclear Medicine Jg. 46 (2021) Nr. 10, S. 807 - 813ISSN: 1536-0229; 0363-9762Online Volltext: dx.doi.org/
-
Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant MesotheliomaIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 2, S. 191 - 194ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase InhibitorsIn: Oncology Research and Treatment Jg. 44 (2021) Nr. 7-8, S. 400 - 407ISSN: 2296-5270; 2296-5262Online Volltext: dx.doi.org/ (Open Access)
-
[⁶⁸Ga]Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinomaIn: Journal of Nuclear Medicine Jg. 62 (2021) Nr. 9, S. 1235 - 1241ISSN: 0022-3123; 0161-5505Online Volltext: dx.doi.org/ (Open Access)
-
In vivo biodistribution of calcium phosphate nanoparticles after intravascular, intramuscular, intratumoral, and soft tissue administration in mice investigated by small animal PET/CTIn: Acta Biomaterialia Jg. 109 (2020) S. 244 - 253ISSN: 1878-7568; 1742-7061Online Volltext: dx.doi.org/
-
Theranostics for Advanced Prostate Cancer : Current Indications and Future DevelopmentsIn: European Urology Oncology Jg. 2 (2019) Nr. 2, S. 152 - 162ISSN: 2588-9311Online Volltext: dx.doi.org/
-
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancerIn: EJNMMI Research Jg. 8 (2018) Nr. 1,ISSN: 2191-219XOnline Volltext: dx.doi.org/ (Open Access)
-
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate CancerIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 58 (2017) Nr. 11, S. 1786 - 1792ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Nuclear Medicine Beyond VISIONIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 7, S. 916 - 917ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
We Can Make a Difference : Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate CancerIn: European Urology Focus Jg. 7 (2021) Nr. 2, S. 227 - 228ISSN: 2405-4569Online Volltext: dx.doi.org/
-
68GA-FAPI PET/CT in the evaluation of Non-Small Cell Lung Cancer (NSCLC)
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S107ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Changes in Tumor-Blood Ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S80ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Comparison of the Safety and Tolerability of Paraaminohippurate (PAH) and Amino Acid (AA) Co-Infusion in Patients with Neuroendocrine Tumours Receiving Peptide Receptor Radionuclide Therapy (PRRT) : A Case Series of Eight Patients
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine October ; 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S579ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
FAPI, PSMA and FDG PET/CT in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) : a triple tracer comparison
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine October ; 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S118 - S119ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Immuntherapie eines Mikrosatelliten-instabilen metastasierten Talgdrüsenkarzinoms der Glandula submandibularis mit Pembrolizumab
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 230 - 231ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Impact of PSMA PET/CT on prostate cancer salvage radiotherapy management : Results from the prospective randomized phase 3 trial [PSMA SRT NCT03582774]In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 5028ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Lesion Quantification Accuracy of Digital 90Y PET Imaging in the Context of Dosimetry in Systemic FAPI Radionuclide Therapy
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S636ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT : Comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S267ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Metastasenfreies Überleben und Fernmetastasen-Muster nach PSMA-PET-gesteuerter Salvage-Radiotherapie bei rezidivierendem oder persistierendem Prostatakarzinom nach Prostatektomie
28. Kongress der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2022 ; 26. bis 28.05.2022, Stuttgart, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 198 (2022) Nr. Supplement 1, S. S117ISSN: 1439-099X; 0179-7158Online Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
2022 ASCO Genitourinary Cancers Symposium, 17.-19.02.2022, San Fransisco,In: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 40 (2022) Nr. 6, Supplement: 2022 ASCO Genitourinary Cancers Symposium,ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : an international multicenter study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S269ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0) : An international multicenter study
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S794 - S795ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/ -
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. Suppl. 6,ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
PSMA PET disease extent for European Association of Urology biochemical recurrence risk groups : An international multicentre study
EAU22: 37th Annual EAU Congress, 01.-04.07.2022, Amsterdam,In: European Urology Jg. 81 (2022) Nr. Supplement 1: Abstracts EAU22 - 37th Annual EAU Congress, S. S291ISSN: 1873-7560; 0302-2838Online Volltext: dx.doi.org/ -
PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy : An international multicenter retrospective studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 5043ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
PSMA-directed imaging and therapy of salivary gland tumors : a single-center retrospective study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S229ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET : An international multicenter retrospective studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. Suppl. 6,ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Radiation Exposure of I-124-MIBG Imaging in Adult Patients with Neuroendocrine Tumours
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S36 - S37ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Re: Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection prior to Radical Prostatectomy and Pelvic Lymph Node Dissection : A Multicenter Prospective Phase 3 Imaging TrialIn: The Journal of Urology Jg. 207 (2022) Nr. 4, S. 930ISSN: 1527-3792; 0022-5347Online Volltext: dx.doi.org/
-
Safety and Effectiveness of Lutetium-177-Prostate-Specific Membrane Antigen (177Lu-PSMA) Therapy Used in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Radium-223 (223Ra) : The RALU Study
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S54 - S55ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra) : Interim analysis of the RALU studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 5040 - 5040ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Superiority of [68Ga]Ga-FAPI-46 over [18F]F-FDG PET/CT for cholangiocarcinoma imaging
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S192 - S193ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S119 - S120ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
VISION read criteria of 68Ga-PSMA-11 PET scans for patient eligibility to 177Lu-PSMA-617 therapy : a simple and reproducible methodology
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S129 - S130ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
A novel theranostic approach for sarcoma : Insights on diagnostic and therapeutic use of FAP-radioligands
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 11 - 12ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 75 - 76ISSN: 1610-0387; 1563-2571; 1610-0379; 0301-0481
-
Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapyIn: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl, S. 9050 - 9050ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Development of a novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP) : An international multicenter study
EANM‘21 ; 34th Annual Congress of the European Association of Nuclear Medicine ; October 20-23, 2021, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. S311 - S312ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105XOnline Volltext: dx.doi.org/ (Open Access) -
Dynamic Ga-68-DOTA PET/CT and Compartmental Modelling to Non-invasively Estimate the Glomerular Filtration RateIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. Suppl. 1,ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058
-
Efficacy and safety of 124-I-MIBG guided high activity 131-I-MIBG therapy of metastatic pheochromocytoma and neuroblastomaIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 290 - S291ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
Evaluation of Dynamic Renal Ga-68-DOTA PET/CT to Monitor the Urinary Efflux and to Estimate the Glomerular Filtration Rate Using a Compartmental Kinetic Modelling ApproachIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 340ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
Ga-68-FAPI for sarcoma imaging : Data from the FAPI-PET prospective observational trialIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. Suppl. 1,ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058
-
Ga-68-versus F-18-PSMA for Cerenkov Luminescence and autoradiography in a prostate cancer mouse modelIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 17ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
Imaging Properties and Quantification Accuracy of Ga-68 and I-124 in a New Generation Preclinical PET/CT System : A Phantom StudyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 227 - S228ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
Impact of PSMA PET/CT on SRT planning : Preliminary results from the randomized phase III trial NCT03582774In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 6, Supplement, S. 30 - 30ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Initial clinical experience with [Y-90]Y-FAPI-46 radioligand therapy for advanced stage solid tumorsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 290ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET) : An explorative, multicenter studyIn: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl, S. 5066 - 5066ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Nomograms to predict outcome after LuPSMA radionuclide therapy in men with metastatic castration-resistant prostate cancer : An international multicenter retrospective studyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 63 - S64ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
PSMA PET and radiomics for the evaluation of liver metastases in castration-resistant prostate cancer patients : A multicenter retrospective studyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 234ISSN: 1619-7089; 1619-7070; 0340-6997; 1432-105X
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : Study ProtocolIn: Cancer Research Jg. 81 (2021) Nr. 13,ISSN: 1538-7445; 0008-5472
-
Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT] : Study protocol NCT04457245In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 6, Supplement, S. TPS172ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Visualization of fibroblast activation after myocardial infarction using 68Ga-FAPI-PETIn: European Heart Journal Jg. 42 (2021) Nr. Supplement_1,ISSN: 0195-668X; 1522-9645Online Volltext: dx.doi.org/ (Open Access)
-
Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection : A multicenter prospective phase III imaging study
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S209ISSN: 1619-7070; 1619-7089Online Volltext: dx.doi.org/ (Open Access) -
Comparison of Lesion Detectability and Image Quality among Digital and Analog PET Systems for Recurrence in Thyroid Cancer Patients Using I-124
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S429ISSN: 1619-7070; 1619-7089Online Volltext: dx.doi.org/ (Open Access) -
Effects of anti-TNF-therapy on osteoblastic activity in ankylosing spondylitis : Results from a prospective study using PET-MRI of SIJ and SPINE
EULAR: Annual European Congress of Rheumatology, 2020, 03.-06.06.2020, Frankfurt,In: Annals of the Rheumatic Diseases (ARD) Jg. 79 (2020) Nr. Suppl. 1, S. 1125 - 1126ISSN: 0003-4967; 1468-2060Online Volltext: dx.doi.org/ (Open Access) -
Impact of PSMA PET/CT on SRT planning: Preliminary results from a randomized phaseIII trial
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. 22ISSN: 1619-7070; 1619-7089Online Volltext: dx.doi.org/ (Open Access) -
Lymphonodular anthracosis in patients undergoing FDG PET/CT for initial lung cancer diagnostics and/or staging is a mayor pitfall : a comparison to the histological gold standard
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S565 - S566ISSN: 1619-7089; 1619-7070Online Volltext: dx.doi.org/ (Open Access) -
Overall survival after177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer : Post-hoc analysis of a prospective phase II trial
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S488ISSN: 1619-7070; 1619-7089Online Volltext: dx.doi.org/ (Open Access) -
Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S487ISSN: 1619-7070; 1619-7089Online Volltext: dx.doi.org/ (Open Access) -
Salvage therapies for PSMA PET-positive nodal recurrent prostate cancerIn: Radiotherapy and Oncology (The Green Journal) Jg. 152 (2020) Nr. Supplement 1, S. 614ISSN: 1879-0887; 0167-8140Online Volltext: dx.doi.org/